Literature DB >> 21416210

Longitudinal study on MRI intensity changes of Machado-Joseph disease: correlation between MRI findings and neuropathological changes.

Yoshihiko Horimoto1, Mitsuhiro Matsumoto, Hiroyasu Akatsu, Akihiro Kojima, Mari Yoshida, Kazuya Nokura, Hiroyuki Yuasa, Eiichi Katada, Takayuki Yamamoto, Kenji Kosaka, Yoshio Hashizume, Hiroko Yamamoto, Shigehisa Mitake.   

Abstract

To disclose the neuropathological progression course of Machado-Joseph disease (MJD), magnetic resonance imaging (MRI) findings of six genetically confirmed MJD cases (four males and two females, including an autopsied female, all unrelated to one another) were further investigated on neurodegeneration. Brain MRI studies were repeated in all cases at different stages of the disease. Ages at the first MRI study ranged from 47 to 65 years (55.2 ± 7.1), with observation periods from 4.5 to 10.6 years (6.95 ± 2.48). We paid particular attention to two types of previously reported MRI findings detectable using T2-weighted images. One is located just outside the internal capsules, and another in the pons. A linear high-intensity change along the internal capsules was detected in all cases, and showed progression during the observation period. A comparison between MRI and autopsy findings suggested that the lesion might reflect degeneration with neuronal loss, astrocytosis, and gliosis in the internal segment of the globus pallidus. A cross-shaped high-intensity change in the pons was well advanced but still incomplete in all cases. In this region, pontine transverse fibers were atrophic, while longitudinal fibers remained intact. Pontine nuclei showed apparent nerve cell loss, and the remaining cells had many 1C2-positive intranuclear inclusions. Since these findings were detected both by lifetime images and by postmortem examination, MRI intensity changes could track the progression of neurodegeneration. Based on a comparison between MRI findings and neuropathology, the degeneration of an internal segment of the globus pallidus (one of the pathological features of MJD) had progressed following the initial symptoms.

Entities:  

Mesh:

Year:  2011        PMID: 21416210     DOI: 10.1007/s00415-011-5992-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  21 in total

1.  Involvement of the cerebral cortex and autonomic ganglia in Machado-Joseph disease.

Authors:  M Yamada; S Hayashi; S Tsuji; H Takahashi
Journal:  Acta Neuropathol       Date:  2001-02       Impact factor: 17.088

2.  A necropsied case of Machado-Joseph disease with a hyperintense signal of transverse pontine fibres on long TR sequences of magnetic resonance images.

Authors:  Y Imon; S Katayama; H Kawakami; Y Murata; M Oka; S Nakamura
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-01       Impact factor: 10.154

3.  Characteristic magnetic resonance imaging findings in Machado-Joseph disease.

Authors:  Y Murata; S Yamaguchi; H Kawakami; Y Imon; H Maruyama; T Sakai; T Kazuta; T Ohtake; M Nishimura; T Saida; S Chiba; T Oh-i; S Nakamura
Journal:  Arch Neurol       Date:  1998-01

4.  CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.

Authors:  Y Kawaguchi; T Okamoto; M Taniwaki; M Aizawa; M Inoue; S Katayama; H Kawakami; S Nakamura; M Nishimura; I Akiguchi
Journal:  Nat Genet       Date:  1994-11       Impact factor: 38.330

5.  Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.

Authors:  Y Trottier; Y Lutz; G Stevanin; G Imbert; D Devys; G Cancel; F Saudou; C Weber; G David; L Tora
Journal:  Nature       Date:  1995-11-23       Impact factor: 49.962

6.  A clinical and pathologic study of a large Japanese family with Machado-Joseph disease tightly linked to the DNA markers on chromosome 14q.

Authors:  Y Takiyama; S Oyanagi; S Kawashima; H Sakamoto; K Saito; M Yoshida; S Tsuji; Y Mizuno; M Nishizawa
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

7.  The 'hot cross bun' sign in the patients with spinocerebellar ataxia.

Authors:  Y-C Lee; C-S Liu; H-M Wu; P-S Wang; M-H Chang; B-W Soong
Journal:  Eur J Neurol       Date:  2009-04       Impact factor: 6.089

Review 8.  CAG repeat disorder models and human neuropathology: similarities and differences.

Authors:  Mitsunori Yamada; Toshiya Sato; Shoji Tsuji; Hitoshi Takahashi
Journal:  Acta Neuropathol       Date:  2007-09-05       Impact factor: 17.088

9.  Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron.

Authors:  B P Drayer; W Olanow; P Burger; G A Johnson; R Herfkens; S Riederer
Journal:  Radiology       Date:  1986-05       Impact factor: 11.105

10.  Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features.

Authors:  A Dürr; G Stevanin; G Cancel; C Duyckaerts; N Abbas; O Didierjean; H Chneiweiss; A Benomar; O Lyon-Caen; J Julien; M Serdaru; C Penet; Y Agid; A Brice
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422

View more
  4 in total

Review 1.  Machado-Joseph Disease: from first descriptions to new perspectives.

Authors:  Conceição Bettencourt; Manuela Lima
Journal:  Orphanet J Rare Dis       Date:  2011-06-02       Impact factor: 4.123

Review 2.  Recent advances in clinical neurogenetics.

Authors:  José Berciano
Journal:  J Neurol       Date:  2012-11-16       Impact factor: 4.849

3.  Clinical Characteristics, Radiological Features and Gene Mutation in 10 Chinese Families with Spinocerebellar Ataxias.

Authors:  Jian-Wen Chen; Li Zhao; Feng Zhang; Lan Li; Yu-Hang Gu; Jing-Yuan Zhou; Hui Zhang; Ming Meng; Kai-Hua Zhang; Wei-Dong Le; Chun-Bo Dong
Journal:  Chin Med J (Engl)       Date:  2015-07-05       Impact factor: 2.628

4.  Microstructural Alterations in Asymptomatic and Symptomatic Patients with Spinocerebellar Ataxia Type 3: A Tract-Based Spatial Statistics Study.

Authors:  Xinwei Wu; Xinxin Liao; Yafeng Zhan; Cheng Cheng; Wei Shen; Mufang Huang; Zhifan Zhou; Zheng Wang; Zilong Qiu; Wu Xing; Weihua Liao; Beisha Tang; Lu Shen
Journal:  Front Neurol       Date:  2017-12-22       Impact factor: 4.003

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.